Rhythm Pharmaceuticals, Inc. - Common Stock (RYTM)
59.43
+0.21 (0.35%)
Rhythm Pharmaceuticals Inc. is a biopharmaceutical company focused on transforming the treatment paradigm for people with rare metabolic disorders, particularly those related to obesity and appetite regulation
The company is dedicated to advancing its research and development efforts to create therapies that target the underlying causes of these conditions. By leveraging innovative science and its expertise in the genetic basis of obesity, Rhythm aims to develop effective treatments that improve the quality of life for patients and address significant unmet medical needs in the field of metabolic health.
Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potentialbenzinga.com
Rhythm Pharmaceuticals targets rare obesity disorders with its drug Imcivree, showing strong growth in sales and potential for significant market expansion
Via Benzinga · December 20, 2024
Forecasting The Future: 14 Analyst Projections For Rhythm Pharmaceuticalsbenzinga.com
Via Benzinga · December 20, 2024
A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 13 Analystsbenzinga.com
Via Benzinga · November 25, 2024
Critical Insights From Rhythm Pharmaceuticals Analyst Ratings: What You Need To Knowbenzinga.com
Via Benzinga · October 25, 2024
What 4 Analyst Ratings Have To Say About Rhythm Pharmaceuticalsbenzinga.com
Via Benzinga · September 18, 2024
A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 4 Analystsbenzinga.com
Via Benzinga · July 25, 2024
5 Analysts Assess Rhythm Pharmaceuticals: What You Need To Knowbenzinga.com
Via Benzinga · April 10, 2024
RYTM Stock Earnings: Rhythm Pharmaceuticals Beats EPS, Misses Revenue for Q2 2024investorplace.com
RYTM stock results show that Rhythm Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
Via InvestorPlace · August 6, 2024
The 3 Best Nasdaq Stocks to Buy in May 2024investorplace.com
Although it’s typically the season for selling, shifting market conditions call for the best Nasdaq stocks to buy in May.
Via InvestorPlace · May 7, 2024
RYTM Stock Earnings: Rhythm Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024investorplace.com
RYTM stock results show that Rhythm Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via InvestorPlace · May 7, 2024
Jim Cramer Is 'Willing To Let This Pharma Stock Catch Fire,' Advises Not To Sell McKessonbenzinga.com
The "Mad Money" host recommended buying some Marvell Technology, and then wait until under $60 to buy the rest.
Via Benzinga · April 19, 2024
Analyst Expectations For Rhythm Pharmaceuticals's Futurebenzinga.com
Via Benzinga · February 22, 2024
Rhythm Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)benzinga.com
Via Benzinga · January 25, 2024
The Analyst Verdict: Rhythm Pharmaceuticals In The Eyes Of 7 Expertsbenzinga.com
Via Benzinga · January 4, 2024
Analyst Expectations for Rhythm Pharmaceuticals's Futurebenzinga.com
Via Benzinga · December 7, 2023
Earnings Scheduled For February 22, 2024benzinga.com
Companies Reporting Before The Bell • Indivior (NASDAQINDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million.
Via Benzinga · February 22, 2024
Rare Genetic Diseases Of Obesity-Focused Rhythm Pharma's Bardet-Biedl Syndrome Drug Meets Primary Goal In Pediatric Trialbenzinga.com
During the R&D event for investors, Rhythm Pharmaceuticals Inc (NASDAQRYTM) released new topline data from its Phase 3 pediatrics trial evaluating one year of setmelanotide in patients aged two and below six years with Bardet-Biedl syndrome (BBS) or proopiomelanocortin (POMC) or leptin recep
Via Benzinga · December 6, 2023
Morgan Stanley Maintains Equal-Weight Rating for Rhythm Pharmaceuticals: Here's What You Need To Knowbenzinga.com
Via Benzinga · October 10, 2023
Benzinga's Top Ratings Upgrades, Downgrades For August 2, 2023benzinga.com
Via Benzinga · August 2, 2023
Earnings Scheduled For November 7, 2023benzinga.com
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSECORR) is estimated to report earnings for its third quarter.
Via Benzinga · November 7, 2023
Why Aaron's Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Sessionbenzinga.com
Gainers Adamis Pharmaceuticals Corporation (NASDAQADMP) shares gained 188.8% to $4.13. The stock is now on the Regulation SHO "threshold security" list.
Via Benzinga · August 1, 2023